Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00781040

Enrollment

273

Registered

2008-10-28

Start date

2006-12-31

Completion date

2019-01-01

Last updated

2019-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Severe sepsis in neutropenic haematological patients

Brief summary

The aim of this study is to find out whether inflammation markers including cardiac markers have predictive value in evaluation of pathogenesis of sepsis in neutropenic haematological patients.

Detailed description

Adult AML and ASCT patients with neutropenic fever. Observation of possible progress to severe sepsis or septic shock. Blood sample collection on days 0-3 (from the beginning of neutropenic fever).

Interventions

OTHERSevere sepsis vs. non-severe sepsis

To compare these two groups

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* diagnosis: acute myeloid leukaemia * age under 70 years * neutropenic fever

Exclusion criteria

* age above 70 years * no neutropenic fever

Design outcomes

Primary

Measure	Time frame	Description
This study evaluates epidemiology, microbiology and outcome of neutropenic fever and severe sepsis in haematological patients with special reference to the kinetics of inflammatory markers.	Within neutropenic period after treatment	This study evaluated epidemiology, microbiology and outcome of neutropenic fever and severe sepsis in haematological patients with special reference to the kinetics of specific inflammatory markers.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026